Sign Up Today and Learn More About AgomAb Therapeutics Stock
Invest in or calculate the value of your shares in AgomAb Therapeutics or other pre-IPO companies through EquityZen's platform.
AgomAb Therapeutics Stock (AGTH)
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
About AgomAb Therapeutics Stock
Founded
2017
Industries
Science and Engineering, Health Care, Biotechnology
AgomAb Therapeutics Press Mentions
Stay in the know about the latest news on AgomAb Therapeutics
Alpha-9's $175m third-round heads latest biotech financings
pharmaphorum • Oct 31, 2024
Agomab Therapeutics Secures $89 Million in Series D Financing
venturecapital • Oct 26, 2024
Erik van den Berg’s Post
linkedin • Aug 03, 2024
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
businesswire • Jul 11, 2024
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
businesswire • Jul 04, 2024
AgomAb Therapeutics Management
Leadership team at AgomAb Therapeutics
Co-founder
Virginia Morello
Chief Executive Officer
Tim Knotnerus
Join now and verify your accreditation status to gain access to:
- AgomAb Therapeutics current valuation
- AgomAb Therapeutics stock price
- Available deals in AgomAb Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in AgomAb Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like AgomAb Therapeutics through EquityZen funds. These investments are made available by existing AgomAb Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell AgomAb Therapeutics stock?
Shareholders can sell their AgomAb Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
